Cathepsin inhibitors in cancer treatment

Details Cathepsin inhibitors in cancer treatment Cathepsin inhibitors in cancer treatment

2000-03-31

2003-08-12

Horlick, Kenneth R. (Department: 1637)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S004300, C514S740000

Reexamination Certificate

active

06605589

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to inhibition of cysteine cathepsins for treating cancer and other human disease states. More particularly the invention relates to the induction of apoptotis cell death in human cancer cells by inhibitors of cysteine cathepsins.
BACKGROUND OF THE INVENTION
Cathepsins (Cats) belong to the papain superfamily of lysosomal cysteine proteases. Cathepsins are involved in the normal proteolysis and turnover of target proteins and tissues as well as in initiating proteolytic cascades by proenzyme activation and in participating in MHC class II molecule expression. Baldwin (1993) Proc. Natl. Acad. Sci., 90: 6796-6800; Mixuochi (1994) Immunol. Lett., 43:189-193.
However, aberrant cathepsin expression has also been implicated in several serious human disease states. Cathepsins have been shown to be abundantly expressed in cancer cells, including breast, lung, prostate, glioblastoma and head
eck cancer cells, (Kos et al. (1998) Oncol. Rep., 5:1349-1361; Yan et al. (1998) Biol. Chem., 379:113-123; Mort et al. (1997) Int. J Biochem. Cell Biol., 29: 715-720; Friedrick et al. (1999) Eur. J Cancer, 35:138-144) and are associated with poor treatment outcome of patients with breast cancer, lung cancer, brain tumor and head
eck cancer. Kos et al, supra. Additionally, aberrant expression of cathepsin is evident in several inflammatory disease states, including rheumatoid arthritis and osteoarthritis. Keyszer (1995) Arthritis Rheum., 38:976-984.
The molecular mechanisms of cathepsin activity are not completely understood. Recently, it was shown that forced expression of cathepsin B rescued cells from serum deprivation-induced apoptotic death (Shibata et al. (1998) Biochem. Biophys. Res. Commun., 251: 199-203) and that treatment of cells with antisense oligonucleotides of cathepsin B induced apoptosis. Isahara et at. (1999) Neuroscience, 91:233-249. These reports suggest an anti-apoptotic role for the cathepsins that is contrary to earlier reports that cathepsins are mediators of apoptosis. Roberts et al (1997) Gastroenterology, 113: 1714-1726; Jones et al. (1998) Am. J Physiol., 275: G723-730.
Cathepsin inhibitor I Z-Phe-Gly-NHO-Bz (CATI-1) is a selective inhibitor of cathepsin activity. Demuth et al. (1996) Biochem. Biophy. Acta, 1295: 179-186. Little is known on the significance of cathepsin inhibition, especially in the fields of biomedical research and therapeutic drug design. Against this backdrop the present invention has been developed.
SUMMARY OF THE INVENTION
The present invention involves the surprising and unexpected discovery that cathepsin inhibitors and methods of use for cathepsin inhibitors trigger cathepsin dependent apoptosis in cancer cells and in cells having aberrant levels of cathepsin.
One aspect of the present invention is a method for inhibiting the growth of tumor cells in a subject by administering to the subject a cathepsin inhibitor. The method can include inducing the tumor cells to become apoptotic.
Another aspect of the invention is a method of treating cancer cells in a subject by administering a therapeutically effective amount of cathepsin inhibitor to the subject. The cancer cells can be solid cancer cells, for example breast cancer and prostate cancer cells, or can be cancer of the white blood cells, for example leukemia.
Another aspect of the invention is a method for inhibiting inflammatory disease in a subject by administering to the subject a cathepsin inhibitor. The inflammatory disease can be rheumatoid arthritis.
Another aspect of the invention is a method for inducing cytotoxicity in a cell by administering a cytotoxic dose of cathepsin inhibitor to the cell.
Another aspect of the invention is a pharmaceutical composition having a substantially purified cathepsin inhibitor and a pharmaceutically acceptable carrier.
Another aspect of the invention is a method for inhibiting growth of a tumor cell by making a recombinant vector that expresses a cathepsin inhibitor and administering the recombinant vector to the tumor cell.
Finally, another aspect of the invention is a method for inducing apoptosis in a cell by expressing a heterologous nucleic acid sequence encoding the cathepsin inhibitory peptide in a host cell having enhanced cathepsin activity as compared to control host cells.


REFERENCES:
patent: 5883121 (1999-03-01), Yamashita et al.
patent: WO 98/49190 (1998-11-01), None
patent: WO 01/44464 (2001-06-01), None
Leto, G. et al., “Effects of E-64 (Cysteine-Proteinase Inhibitor) and Pepstatin (Aspartyl-Proteinase Inhibitor) on Metastasis Formation in Mice with Mammary and Ovarian Tumors”, In Vivo, vol. 8, pp. 231-236, 1994.*
Xing, R. et al., “Control of Breast Tumor Cell Growth Using a Targeted Cysteine Protease Inhibitor”, Cancer Res., vol. 58, pp. 904-909 (1998).*
Sivaparvathi et al., “Expression of cathepsin D during the progression of human gliomas”, Neurosci. Lett., vol. 208, pp. 179-174, 1996.*
Soderstrom, K-O. et al., “Expression of Acid cysteine Proteinase Inhibitor (ACPI) in the Normal Human Prostate, Benign Prostatic Hyperplasia and Adenocarcinoma”, Int. J. Cancer, vol. 62, pp. 1-4 (1995).*
Krueger, S., Haeckel, C., Buehling, F., and Roessner, A. (1999) “Inhibitory Effects of Antisense Cathepsin B cDNA Transfection on Invasion and Motility in a Human Osteosarcoma Cell Line”. Cancer Research, 59:6010-6014.
Zhu, D.-M. and Uckun, F.M. (2000) “Z-Phe-Gly-NHO—Bz, an Inhibitor of Cysteine Cathepsins, Induces Apoptosis in Human Cancer Cells”, Clinical Cancer Research, 6:2064-2069.
Zhu, D.-M. and Uckun, F.M. (2000) “Cathepsin Inhibition Induces Apoptotic Death in Human Leukemia and Lymphoma Cells”. Leukemia and Lymphoma, 39:343-354.
Blandino GB, Levine AJ, Oren M (1999). Mutuant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.Onogene18: 477-485.
Brimmell M, Mendiola R, Mangion J, Packham G (1998). BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability.Oncogene16: 1803-1812.
Chow SC, Weiss M, Kass GE, Holmstrom TH, Eriksson JE, Orrenius S (1995). Involvement of multiple proteases during Fas-mediated apoptosis in T lymphocytes.FEBS Lett364: 134-138.
Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Vegna ML, Guglielmi C, Mancini F, Guiliacci S, Sacchi A, Mandelli F, Foa R (1998). p53 Expressions in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.Blood91: 4342-4349.
Demuth, HU, Schierhorn A, Bryan P, Hofke R, Kirschke H, and Bromme D (1996). N-peptidyl, O-acyl hydroxamates: comparison of the selective inhibition of serine and cysteine proteinases.Biochim Biophys Acta1295: 179-186.
Doman RK, Perez M, Donato NJ (1999). JNK and p53 stress signaling cascades are altered in MCF-7 cells resistant to tumor necrosis factor-mediated apoptosis.J. Interferon Cytokine Res19: 261 - 269.
Duffy MJ (1992). The role of proteolytic enzymes in cancer invasion and metastasis.Clin Exp Metastasis10: 145-155.
Fearnhead HO, Dinsdale D, Cohen GM (1995). An interleukin-1 beta-converting enzyme-like protease is a common mediator of apoptosis in thymocytes.FEBS Lett375: 283-288.
Friedrich B, Jung K, Lein M, Turk I, Rudolph B, Mampel G, Schnorr D, and Loening SA (1999). Cathepsin B,H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue.Eur J Cancer35: 138-144.
Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA (1998). Inhibition of human caspases by peptide-based and macromolecular inhibitors.J Biol Chem273: 32608-32613.
Green DR, Reed JC (1998). Mitochondria and apoptosis.Science281: 1309-1312.
Guitiérrez MI, Cherney B, Hussain A, Mostowski H, Tosato G, Magrath I, Bhatia K (1999). Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.Cancer Res59: 696-703.
Heidtmann HH, Salge U, Abrahamson M, Bencina M, Kastalic L, Kopitar-Jerala N, Turk V, and Lah TT (1997). C

Affiliated with

Also associated with

Rating

Cathepsin inhibitors in cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cathepsin inhibitors in cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cathepsin inhibitors in cancer treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3115987